What made Teladoc shares tank 40% in extended trading? | Invezz
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Apr 27, 2022
Teladoc Health Inc shares (NYSE: TDOC) tanked 40% in extended trading on Wednesday after the virtual healthcare company said it took an impairment charge worth $6.60 billion in Q1 and lowered its guidance for the full year.
Teladoc Q1 earnings snapshot
Lost $6.67 billion in fiscal Q1 versus the year-ago figure of $200 million.Per-share loss of $41.58 was massively wider than last year’s $1.31 only.Revenue jumped 24.5% year-over-year to $565.4 million in the first quarter.FactSet consensus was for a slightly higher $569 million in revenue.
Much of the goodwill impairment was related to $18.5 billion acquisition of Livongo. CFO Mala Murthy said in the earnings press release:
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
The goodwill impairment was triggered by sustained decline in our share price with valuation and size of it driven by factors, including increased discount rate and decreased market multiples for a relevant peer group of high-growth digital healthcare companies, and updates to our forecast cash flows consistent with revised guidance disclosed today.
Guidance and Karen Firestone’s remarks
For the full financial year, Teladoc now forecasts its revenue to fall between $2.4 billion and $2.5 billion. It expects up to $265 million in adjusted EBITDA this year. On CNBC’s “Closing Bell”, Aureus Asset Management’s Karen Firestone said:
It’s a company that had a fantastic business idea for a pandemic but it didn’t come up with a strategy for the post COVID world. So now they’re just losing share again, they’re losing money. No one knows what the growth rate will be, or if there is one.
The stock is now down more than 60% for the year.
68% of retail CFD accounts lose money
Health & pharmaceuticals
Stocks & Shares